PURPOSE: Anthracyclines have been utilized in the treatment of children with acute lymphoblastic leukemia (ALL). Recent studies have shown that anthracyclines may induce toxicity in the vascular endothelium. This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy. METHODS: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy children. The cumulative dose of anthracyclines in the ALL patients was 142.5±18.2/m(2). The last anthracycline dose was administered to the patients 2 to 85 months prior to their examination using BAR. The diameter of the brachial artery was measured in both groups using echocardiography, and BAR was calculated as the percentage change in the arterial diameter after release of the cuff relative to the baseline vessel diameter. RESULTS: In the anthracycline-treated group, BAR was observed to be 3.4%±3.9%, which was significantly lower than that observed in the control group (12.1%±8.0%, P<0.05). The time elapsed after the last anthracycline treatment and the age at the time of treatment did not affect the change in BAR (P=0.06 and P=0.13, respectively). CONCLUSION: These results provided evidence that treatment of ALL patients with anthracycline results in endothelial dysfunction. A larger cohort study and a longer follow-up period will be required to clarify the relationship between endothelial dysfunction resulting from anthracycline treatment for childhood ALL and occurrence of cardiovascular diseases later in life.
PURPOSE:Anthracyclines have been utilized in the treatment of children with acute lymphoblastic leukemia (ALL). Recent studies have shown that anthracyclines may induce toxicity in the vascular endothelium. This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy. METHODS: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy children. The cumulative dose of anthracyclines in the ALL patients was 142.5±18.2/m(2). The last anthracycline dose was administered to the patients 2 to 85 months prior to their examination using BAR. The diameter of the brachial artery was measured in both groups using echocardiography, and BAR was calculated as the percentage change in the arterial diameter after release of the cuff relative to the baseline vessel diameter. RESULTS: In the anthracycline-treated group, BAR was observed to be 3.4%±3.9%, which was significantly lower than that observed in the control group (12.1%±8.0%, P<0.05). The time elapsed after the last anthracycline treatment and the age at the time of treatment did not affect the change in BAR (P=0.06 and P=0.13, respectively). CONCLUSION: These results provided evidence that treatment of ALL patients with anthracycline results in endothelial dysfunction. A larger cohort study and a longer follow-up period will be required to clarify the relationship between endothelial dysfunction resulting from anthracycline treatment for childhood ALL and occurrence of cardiovascular diseases later in life.
Authors: Ching-Hon Pui; Deqing Pei; John T Sandlund; Dario Campana; Raul C Ribeiro; Bassem I Razzouk; Jeffrey E Rubnitz; Scott C Howard; Nobuko Hijiya; Sima Jeha; Cheng Cheng; James R Downing; William E Evans; Mary V Relling; Melissa Hudson Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Damon Duquaine; Glenn A Hirsch; Anjan Chakrabarti; Zhenguo Han; Chris Kehrer; Robert Brook; Joy Joseph; Anne Schott; B Kalyanaraman; Jeanette Vasquez-Vivar; Sanjay Rajagopalan Journal: Vasc Med Date: 2003-05 Impact factor: 3.239
Authors: Jessica E Caterini; Kate Rendall; Barbara Cifra; Jane E Schneiderman; Felix Ratjen; Mike Seed; Tammy Rayner; Ruth Weiss; Brian W McCrindle; Michael D Noseworthy; Craig A Williams; Alan R Barker; Gregory D Wells Journal: Physiol Rep Date: 2022-05
Authors: Ibrahim Y Abdelgawad; Karim T Sadak; Diana W Lone; Mohamed S Dabour; Laura J Niedernhofer; Beshay N Zordoky Journal: Pharmacol Ther Date: 2020-12-01 Impact factor: 12.310
Authors: Ibrahim Y Abdelgawad; Kevin Agostinucci; Somia G Ismail; Marianne K O Grant; Beshay N Zordoky Journal: Cells Date: 2022-06-21 Impact factor: 7.666
Authors: Marco Crocco; Giuseppe d'Annunzio; Alberto La Valle; Gianluca Piccolo; Decimo Silvio Chiarenza; Carolina Bigatti; Marta Molteni; Claudia Milanaccio; Maria Luisa Garrè; Natascia Di Iorgi; Mohamad Maghnie Journal: Life (Basel) Date: 2021-12-29